ERCC6L and breast fibrocystic disease: Our results first showed that ERCC6L deletion significantly reduced the number of TEBs and ductal branches and significantly inhibited the extension of mammary branch ducts into the fat pad in both 6-week-old and 8-week-old mice, which suggested mammary dysplasia.